- Home
- CRBP vs TNYA Comparison
CRBP vs TNYA Comparison
Compare CRBP & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- TNYA
- Stock Information
- Founded
- CRBP 2009
- TNYA 2016
- Country
- CRBP United States
- TNYA United States
- Employees
- CRBP N/A
- TNYA N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- CRBP Health Care
- TNYA Health Care
- Exchange
- CRBP Nasdaq
- TNYA Nasdaq
- Market Cap
- CRBP 110.3M
- TNYA 111.1M
- IPO Year
- CRBP N/A
- TNYA 2021
- Fundamental
- Price
- CRBP $8.90
- TNYA $0.70
- Analyst Decision
- CRBP Strong Buy
- TNYA Strong Buy
- Analyst Count
- CRBP 10
- TNYA 5
- Target Price
- CRBP $53.56
- TNYA $8.60
- AVG Volume (30 Days)
- CRBP 124.3K
- TNYA 2.4M
- Earning Date
- CRBP 08-05-2025
- TNYA 08-15-2025
- Dividend Yield
- CRBP N/A
- TNYA N/A
- EPS Growth
- CRBP N/A
- TNYA N/A
- EPS
- CRBP N/A
- TNYA N/A
- Revenue
- CRBP N/A
- TNYA N/A
- Revenue This Year
- CRBP N/A
- TNYA N/A
- Revenue Next Year
- CRBP $270.04
- TNYA N/A
- P/E Ratio
- CRBP N/A
- TNYA N/A
- Revenue Growth
- CRBP N/A
- TNYA N/A
- 52 Week Low
- CRBP $4.64
- TNYA $0.36
- 52 Week High
- CRBP $61.89
- TNYA $4.01
- Technical
- Relative Strength Index (RSI)
- CRBP 53.56
- TNYA 47.56
- Support Level
- CRBP $9.10
- TNYA $0.64
- Resistance Level
- CRBP $9.80
- TNYA $0.80
- Average True Range (ATR)
- CRBP 0.62
- TNYA 0.08
- MACD
- CRBP 0.01
- TNYA -0.02
- Stochastic Oscillator
- CRBP 31.45
- TNYA 17.34
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.